ORAGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ORAGENICS, INC. (OGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.84% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2024-03-29
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.84%, a 56.63% increase from fiscal 2022.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.09%, a 108.78% increase from fiscal 2021.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.48%, a 10.84% decline from fiscal 2020.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.66%, a 31.69% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2023-12-31 | 4.84% 10-K · filed 2024-03-29 |
| 2022-12-31 | 3.09% 10-K · filed 2024-03-29 |
| 2021-12-31 | 1.48% 10-K · filed 2023-04-17 |
| 2020-12-31 | 1.66% 10-K/A · filed 2022-07-29 |
| 2019-12-31 | 2.43% 10-K · filed 2021-03-01 |
| 2018-12-31 | 3.06% 10-K · filed 2020-03-04 |
| 2016-12-31 | 2.40% 10-K · filed 2018-02-16 |
| 2015-12-31 | 2.27% 10-K · filed 2017-02-27 |
| 2014-12-31 | 2.77% 10-K · filed 2016-03-30 |
| 2013-12-31 | 2.80% 10-K · filed 2015-02-27 |
| 2011-12-31 | 2.48% 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |